Rigel PharmaceuticalsRIGL
Recorded

Rigel Pharmaceuticals Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration27 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Farzin HaqueBiotechnology Analyst

Hi, everyone. Let's get started. My name is Farzin Haque, one of the biotech analysts at Jefferies. It's my pleasure to introduce Raul Rodriguez, CEO of Rigel Pharmaceuticals. He's going to present us, and we can take some questions at the end if we have any. Thank you for joining us, Raul.

Raul RodriguezCEO

Thank you, Farzin, and thank you to our colleagues at Jefferies for the invitation. It's a pleasure to be with you today. Importantly, these are our forward-looking statements, important statements about my presentation for you today. It's a lot of small print, but it is available on our website for you to review at your leisure. Let me tell you about Rigel. Rigel is a company that has gone through several transformations of the company, and really, it's exciting to be at a company where every few years, it's very much a different company. I'll tell you what we've done in the recent past, and in this presentation, what our plans are going forward. Our transformational growth strategy has four key strategic objectives. Grow our commercial business. In this presentation, I'll show you how we've grown it to date, what our plans are for the future.

Raul RodriguezCEO

In-license or bring in additional molecules to add to our portfolio and our pipeline, and I'll show you what we've done over the last several years, what our plans are for the future of that. Advance our pipeline. Here, we'll discuss one of the really exciting opportunities that we have in terms of our own pipeline that's coming forward, and we'll have data next month at the ASH meeting. All this is coupled together with financial discipline, maintaining financial discipline so we can afford to do and pay for what we're proposing to do here today. I'll share with you some of the latest results in that. All four of these strategic objectives work together. They're interlocking and codependent, and it's important to execute across all of them. I hope at this presentation, I can demonstrate to you how exactly we're doing that.

Raul RodriguezCEO

Let me start here with one of our most recent examples of this strategy in action. VEPPANU is a product we acquired in Q3. The deal closed in June. We began working on introducing the product immediately after that, and ahead of commercial availability. We incorporated it into our distribution network and immediately began working all the contractual things to get those done so that we could have this product available to patients very quickly. In the first six weeks, it launched mid-August, we were able to achieve $6.6 million in sales. Really impressive number. That was over 100 patients in clinics received product in that six-week period. Many of them, of the early patients, received, the majority, in fact, received their first refill even within Q3, which is a very good early sign.

Raul RodriguezCEO

We have strong coverage across commercial and Medicare payers, and healthcare provider engagement has been going very well as we focus on high prescribers in metastatic breast cancer in this area. We are executing on our plan, highlighting the data that we have supporting VEPPANU and its approval, and its differentiated mechanism of action. I will tell you a bit more about that in a minute. An exciting Q3, one of the most exciting times in our history in having a new growth engine for the company. How are we doing in terms of growing the commercial business? Quite good. Here we see what we have done over the last five years, where we have grown our commercial business by an average of 35% per year over this period of time. TAVALISSE, our main product in deep green there, has grown very nicely in this period.

Raul RodriguezCEO

Subsequently, we have added REZLIDHIA in 2022, and you begin to see that in light green. Then we added GAVRETO in 2024, in deeper green. Our guidance is to continue to grow that, excluding even VEPPANU. What is exciting about this is what is coming in the future. VEPPANU will be our potential largest product at the company, and it is a significant opportunity in a very large market. It will be the driver of growth for our business in the near term and in the intermediate term. We are very excited about the VEPPANU opportunity for us. In the more intermediate and longer term, the key driver of growth will be R289, our internally discovered molecule. It is an IRAK1/4 inhibitor, which we have in development for lower-risk MDS.

Raul RodriguezCEO

This has a potential to be greater than a billion-dollar opportunity and will drive the commercial growth of the business in 2030s and beyond. I will tell you a little bit more about each of these two molecules that are the near-term and the longer-term future for the growth of the business. This past quarter, we achieved $72 million in net product sales, our largest quarterly sales number ever. VEPPANU contributed $6.6 million, TAVALISSE continued to grow and generated $4.6 million, REZLIDHIA $9.9 million, and GAVRETO $9.8 million. A little bit of decline there in sales. It is a very stable product, generally selling about $10 million a quarter. Overall, for the three quarters of this calendar year, very nice growth over last year comparable period, as you see here. A very good quarter for us in Q3, in addition to launching VEPPANU.

Raul RodriguezCEO

VEPPANU is indicated for patients that are ER-positive, estrogen receptor-positive, HER2-negative, and have an ESR1-mutated advanced or metastatic breast cancer patients. To tell you a little bit about the market opportunity, in the U.S., there are about 170,000 metastatic breast cancer patients. Of those, about 119,000 are ER-positive, HER2-negative patients. Of those patients, after endocrine and CDK4/6 therapy, generally ESR1 mutations evolve, and that accounts for about 47,000 patients. Of those, about 28,000 are diagnosed having this mutation, and about 20,000 are treated in the second line and beyond, which is where we are indicated. That 20,000 patients are an attractive market opportunity. If you think about the numbers associated with it is well over a billion dollars opportunity in that segment of the population.

Raul RodriguezCEO

We're excited about the product, and with it, what we were able to deliver in the first six weeks only, 100 patients. As I mentioned, most of those received their second refill, their second shipment. We reached many prescribers and many accounts over the six-week period, and we continue to make very good progress on these. This is available on our website, by the way. Exciting also is that we were able to receive lots of high prior authorization rates, 88% overall, 90+% for Medicare, 80+% for commercial insurance at this point. So very attractive. We were able to get the product to patients very quickly, median of four days for these patients in this first six weeks of product. So quick to get the patients to get their drug, and we provide a wide range of support to these patients.

Raul RodriguezCEO

This is a hub that we had in place prior, so now we've added this as a product. So we were able to leverage that very nicely in helping them get coverage support and other assistance that is compliant so that we can help them access the product. Let me tell you what excited us the most about VEPPANU. It's a PROTAC, which is different than any other drug that's out there today, cancer or not cancer. It's an area of tremendous focus in terms of how we address molecules in difficult-to-target areas such as this. It's established that estrogen receptor degradation is an important therapeutic approach to treating this type of metastatic breast cancer. The other SERDs, the more traditional approach, is to have a molecule that binds to the estrogen receptor and changes its conformation, causes it to be more likely to be degraded.

Raul RodriguezCEO

There's degradation, and the degradation, as we've seen in the preclinical studies, have been wide-ranging. With PROTAC, it's a very different approach. PROTAC uses the cell's own disposal system to get rid of unwanted protein. What the molecule does, it's a bifunctional molecule. One side attaches to the estrogen receptor, the other to ubiquitin E3 ligase. It brings those two close together in terms of where they sit, and then the ER is polyubiquitinated with tiny little ubiquitin proteins. Once that happens, that tags it for destruction by the cell's proteasome, and things are destroyed, the PROTAC molecule is released, and does this again and again and again. The consequence of that is that we have a high level of ER degradation with the PROTAC, as you see here.

Raul RodriguezCEO

So we're excited about having this novel mechanism in this area, and we focused on that elegant process and the results that it produced. It produced five months of progression-free survival, PFS, versus fulvestrant, an older SERD, only producing 2.1 months. This is part of our registrational study and is part of the label. So we're excited about having something that is the first and only approved PROTAC that has features that make it a very attractive molecule in this breast cancer space. Let me move on to in-licensing and business development. Here, we've been very successful over the last handful of years. We're looking for assets that are differentiated in hematology, oncology, and related areas. In 2022, we acquired REZLIDHIA and launched it in 2022. This is indicated for relapse refractory IDH1 mutant AML. In 2024, we acquired GAVRETO.

Raul RodriguezCEO

This is a product that is indicated for RET-positive non-small cell lung cancer and thyroid cancer, and we launched that product in 2024. In 2026, yet again, we acquired VEPPANU, and we've launched the product in August of 2026. So every two years, we seemingly are able to acquire a new product, launch it, integrate it into our system, and work to making it a success. We're looking for late-stage programs, things that have completed their registrational trial, and either are at NDA review or NDA is coming shortly, or the product's just been approved. So we're able to launch it very quickly after we acquire the product. It's important that they are synergistic to our current commercial effort, so we don't have to grow our commercial business too much infrastructure in order to launch that product.

Raul RodriguezCEO

What that creates, because it's a late-stage product, we integrate it, we launch it quickly, is that it rapidly becomes accretive and cash-generating. That's a very attractive feature of all these three products that we acquired in the last handful of years. So, excited about that opportunity. We'll continue to further this strategy and look at additional molecules that we could bring in that are synergistic to what we have. Let me move to our development pipeline. I'd like to tell you a little bit about the first two things on this slide. R289 is our IRAK1/4 inhibitor in development in a phase I-B study for relapse refractory lower-risk MDS. And we're going to soon consider other indications and lines of therapy for this molecule. I'll tell you quite a bit more about this.

Raul RodriguezCEO

Vepdeg, which is VEPPANU, is a PROTAC, and we have ongoing studies in combinations with our partner, Arvinas and Pfizer. They're completing a bunch of studies. I'll share those with you. And we're considering which studies ourselves to launch going forward to highlight the mechanistic differences of this molecule and how it's useful in a post-SERD setting. I won't talk very much about olutasidenib or REZLIDHIA further, but we are working with strategic collaborations. MD Anderson is one of our largest collaborators in exploring how olutasidenib in monotherapy and combination therapy work in IDH1-mutant AML and other malignancies. And with another organization, the CONNECT Group, we're working on studying this molecule in high-grade gliomas as well. But I'll talk about the first two a bit more. R289 in lower-risk MDS. Here's the landscape for lower-risk MDS.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day